Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy cover art

Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy

Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy

Listen for free

View show details

About this listen

We are pleased to present Part 3 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.

Part 3 of this series provides peer-to-peer physician perspectives on strategies for staying on CDK4/6 inhibitor therapy.

Topics include:

  1. Clinical trial experience managing adverse events of CDK4/6 inhibitors in early breast cancer
  2. Treatment persistence during real-world adjuvant CDK4/6 inhibitor therapy

Discussants:

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University

Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies

Director, Translational Research, Breast Oncology Program

Assistant Professor of Medicine, Harvard Medical School

Massachusetts General Hospital

Boston, MA

Sponsored by Lilly
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.